chemotherapy induced neutropenia epidemiology forecast insight
DelveInsight’s ‘Chemotherapy Induced Neutropenia - Epidemiology Forecast–2034’ report delivers an in-depth understanding of the Chemotherapy Induced Neutropenia, historical and forecasted epidemiology as well as the Chemotherapy Induced Neutropenia epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2021-2034
Chemotherapy Induced Neutropenia Disease Understanding
Chemotherapy-Induced Neutropenia is the primary dose-limiting toxicity in patients with cancer treated with chemotherapy. It can lead to febrile neutropenia (FN), and it is associated with increased morbidity and early mortality, increased medical costs, and disruptions in potentially curative treatments.
Chemotherapy Induced Neutropenia Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by the Total number of patients on chemotherapy, Risk-specific chemotherapy patient pool for Chemotherapy Induced Neutropenia, and Total incident cases of Chemotherapy Induced Neutropenia by cancer type scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.
Chemotherapy Induced Neutropenia Detailed Epidemiology Segmentation
- In the 7MM, the total estimated number of cancer patients on chemotherapy was 1,790,618 in 2020.
- In 2020, the highest number of cancer patients on chemotherapy were accounted by the US making up to 691,906, while the EU5 countries accounted for 778,973 number of cancer patients on chemotherapy. Japan ranked second among 7MM countries with 319,740 cancer patients on chemotherapy in 2020.
- Assessments as per DelveInsight show that there were 484,334 cases at intermediate-high risk for Chemotherapy Induced Neutropenia, and 207,572 cases at low risk for Chemotherapy Induced Neutropenia in the United States, in 2020.
- In 2020, the total number of cases of Chemotherapy Induced Neutropenia in the 7MM was 903,597. The US accounted for a majority of cases in the 7MM with 383,339 cases.
- The Chemotherapy Induced Neutropenia cases are included from various cancers such as breast, lung, ovarian, AML, lymphoma, and other cancers. Out of all cancers, in 2020, the highest Chemotherapy Induced Neutropenia cases was from breast cancer i.e. 99,944 cases. Furthermore, 2,354 Chemotherapy Induced Neutropenia cases in AML were the lowest among all cancers, in the US.
- Among the European countries, Germany had the highest cases of Chemotherapy Induced Neutropenia with 96,877 cases, followed by the UK which had 78,494 cases of Chemotherapy Induced Neutropenia in 2020. On the other hand, Spain had the lowest number of Chemotherapy Induced Neutropenia cases in 2020, i.e. 46,167.
- In 2020, Japan accounted for 153,260 cases of Chemotherapy Induced Neutropenia, which is second-highest after the US among 7MM countries.
Scope of the Report
- The report covers the descriptive overview of Chemotherapy Induced Neutropenia, explaining risk factors, symptoms, pathophysiology, biomarkers, and diagnosis.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden of Chemotherapy Induced Neutropenia.
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM, including the Total number of patients on chemotherapy, Risk-specific chemotherapy patient pool for Chemotherapy Induced Neutropenia, and Total incident cases of Chemotherapy Induced Neutropenia by cancer type.
Report Highlights
- 10-Year Forecast of Chemotherapy Induced Neutropenia
- 7MM Coverage
- Total number of patients on chemotherapy
- Risk-specific chemotherapy patient pool for Chemotherapy Induced Neutropenia
- Total incident cases of Chemotherapy Induced Neutropenia by cancer type
Key Questions Answered
- What are the disease risk and burdens of Chemotherapy Induced Neutropenia?
- What is the historical Chemotherapy Induced Neutropenia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Chemotherapy Induced Neutropenia at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Chemotherapy Induced Neutropenia?
- Out of the above-mentioned countries, which country would have the highest incident population of Chemotherapy Induced Neutropenia during the forecast period (2025-2034)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2025-2034)?
Reasons to buy
The Chemotherapy Induced Neutropenia report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the 7MM Chemotherapy Induced Neutropenia epidemiology forecast.
- The Chemotherapy Induced Neutropenia epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
- The Chemotherapy Induced Neutropenia epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
